Price
No data yet.
Social Signal Score
Analyst Ratings
37 analystsRevenue
$1.12BAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kyle W. Gano
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Beta
- 0.33
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 6.82
Financials
Revenue
$1.12B+17622.2%Net Income
$206.50MEBITDA
$328.00MFree Cash Flow
$383.60MEPS (diluted)
$1.96Shares Outstanding (diluted)
105.20M+21.1%Operating Expenses
$718.10MCash & Debt
$737.90MReturn of Capital
$92.10MRevenue by Segment (annual)
$2.86BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.86B | $478.60M | $4.81 |
| 2024 | $2.36B | $341.30M | $3.40 |
| 2023 | $1.89B | $249.70M | $2.56 |
| 2022 | $1.49B | $154.50M | $1.61 |
| 2021 | $1.13B | $89.60M | $0.95 |
| 2020 | $1.05B | $407.30M | $4.37 |
| 2019 | $788.10M | $37.00M | $0.40 |
| 2018 | $451.20M | $21.11M | $0.22 |
| 2017 | $161.63M | $-142.54M | $-1.62 |
| 2016 | $15.00M | $-141.09M | $-1.63 |
| 2015 | $19.77M | $-88.93M | $-1.05 |
| 2014 | $0.00 | $-60.54M | $-0.81 |
| 2013 | $2.92M | $-46.09M | $-0.69 |
| 2012 | $53.14M | $5.03M | $0.08 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NBIX's reported EPS growth of 37.5% a year over 13 years. Historical EPS growth of 37% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $17.86
- Implied price
- $517.92
- Return from $150.57
- 28.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $257.50 — today's price is already 41.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| 20.0% | 10.8% | 14.7% | 18.2% | 21.3% | 24.1% |
| 25.0% | 15.4% | 19.5% | 23.1% | 26.3% | 29.3% |
| 30.0% | 20.0% | 24.3% | 28.0% | 31.4% | 34.4% |
| 35.0% | 24.6% | 29.1% | 33.0% | 36.4% | 39.6% |
| 40.0% | 29.3% | 33.8% | 37.9% | 41.5% | 44.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+25.00%Social Signal Score
Mentions (45)
- Newsmarketbeat.com·12h ago·Neutral
Neurocrine Biosciences Sees INGREZZA Growth, Awaits Key 2027 Trial Results Neurocrine Biosciences NASDAQ: NBIX expects continued growth from its largest medicine, INGREZZA, despite pricing pressure, while preparing for multiple clinical trial readouts in 2027, executives said at a Jefferies-hosted discussion.
View source ↗ - Newszacks.com·2d ago·Positive
Neurocrine Biosciences (NBIX) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·6d ago·Positive
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·13d ago·Neutral
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newszacks.com·13d ago·Positive
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Neurocrine Biosciences: Breaking Down A Solid Quarter
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Neurocrine Biosciences: Breaking Down A Solid Quarter Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17% year-over-year sales growth to $801 million on strong volume gains. The Soleno Therapeutics acquisition and VYKAT XR approval expand NBIX's rare disease portfolio, with VYKAT XR showing strong initial adoption.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free Neurocrine Biosciences is reiterated as a buy with a new fair value of $195.80, 19% above the recent price. The investment thesis centers on NBIX's underappreciated early research engine, now valued using an industry productivity rate, materially lifting fair value. Q3 results exceeded expectations: INGREZZA and CRENESSITY both outperformed, but VYKAT XR faces ongoing safety and patent risks.
View source ↗ - News (RSS)investing·19d ago·Neutral
Why is Neurocrine Biosciences stock surging today?
View source ↗ - Newsprnewswire.com·19d ago·Negative
…t Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8 in Colorado Springs, Colo. Through a special industry-sponsored session, "Inspired by Patients, Driven by Science: The Neurocrine Story," Neurocrine will take attendees behind the science, challenges, and b…
View source ↗ - Newszacks.com·19d ago·Positive
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.
View source ↗ - News (RSS)fool·19d ago·Positive
Neurocrine (NBIX) Q3 2026 Earnings Call Transcript Record $1.1B revenue marks transformative quarter for diversified biotech.
View source ↗ - News (RSS)seekingalpha·19d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Neurocrine Biosciences Q3 Earnings Call Highlights Neurocrine Biosciences NASDAQ: NBIX reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability, supported by growth across its three marketed medicines: INGREZZA, CRENESSITY and VYKAT XR.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·20d ago·Positive
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates Neurocrine Biosciences (NBIX) came out with quarterly earnings of $3.29 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.04 per share a year ago.
View source ↗ - Newszacks.com·20d ago·Neutral
Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsprnewswire.com·20d ago·Positive
…illion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026. "Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class …
View source ↗ - Newszacks.com·23d ago·Positive
Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsprnewswire.com·27d ago·Neutral
…analyses to be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference SAN DIEGO, Oct. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with INGREZZA® (valbenazine) capsules. The findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, taking place Oct. 26-29 in Sa…
View source ↗ - Newsfool.com·28d ago·Negative
Where Will Neurocrine Biosciences Be in 5 Years? Ingrezza remains Neurocrine's biggest revenue driver, with sales growing 15%. Two late-stage drug candidates face important clinical milestones in 2027.
View source ↗ - Newsprnewswire.com·31d ago·Positive
…ment of hyperphagia, potentially complementing behavioral and environmental approaches SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a publication of expert perspectives highlighting hyperphagia in Prader-Willi syndrome (PWS) as a complex, neurobiologically driven condition that extends beyond excessive hunger and requires comprehensive assessment and management across the patient lifespan. The publication provides insights from an internati…
View source ↗ - News (Marketaux)gurufocus.com·32d ago·Positive
Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Undervalued -- GF Score: 90/100 On October 20, 2026, Neurocrine[+233 characters]
View source ↗ - Newsprnewswire.com·33d ago·Neutral
…nitiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease. NBI-'567 is an orally administered, M1/M4 (M1 preferring) selective muscarinic agonist being evaluated as an adjunctive treatment for cognitive impairment in Alzhe…
View source ↗ - Newsprnewswire.com·37d ago·Neutral
…ing needs and inform education, support strategies, and coordination across care teams SAN DIEGO, Oct. 16, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve throughout a patient's life. The findings will be presented at the Endocrine Nurses Society Annual Symposium 2026, taking place Oct. 16-17 in Phoenix.
View source ↗ - Newszacks.com·40d ago·Neutral
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newszacks.com·40d ago·Positive
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsprnewswire.com·41d ago·Neutral
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
View source ↗ - Newsprnewswire.com·53d ago·Positive
…id retention, hyperglycemia, hirsutism and hypertrichosis — during VYKAT XR treatment SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in P…
View source ↗ - Newsprnewswire.com·55d ago·Neutral
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D. SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.
View source ↗ - Newsmarketbeat.com·60d ago·Neutral
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company's efforts to diversify beyond its largest product, INGREZZA.
View source ↗ - News (RSS)seekingalpha·67d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.
View source ↗ - Newszacks.com·89d ago·Negative
NBIX vs. TEVA: Which Drugmaker Is the Better Investment? Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
View source ↗ - News (RSS)seekingalpha·92d ago·Neutral
Neurocrine Biosciences: 'House Full Of Options'
View source ↗ - Newsseekingalpha.com·92d ago·Positive
Neurocrine Biosciences: 'House Full Of Options' Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation.
View source ↗ - Newszacks.com·94d ago·Positive
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
View source ↗ - Newszacks.com·94d ago·Positive
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
View source ↗ - Newszacks.com·94d ago·Positive
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
View source ↗ - Newszacks.com·97d ago·Neutral
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.
View source ↗ - Newsprnewswire.com·102d ago·Neutral
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes Mean improvements in the patien
View source ↗ - Newsreuters.com·102d ago·Negative
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported in patients with the rare genetic disorder.
View source ↗
Earnings
Wed, Feb 10(in 3 months)
Consensus estimate $2.07 per share
Typical surprise +29.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$3.29 vs $1.91beat
- Thu, Jul 30$2.85 vs $1.85beat
- Tue, May 5$1.91 vs $1.22beat
- Wed, Feb 11$1.88 vs $1.80beat
- Tue, Oct 28$2.04 vs $1.58beat
- Wed, Jul 30$1.06 vs $0.98beat
Estimates and results for NBIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NBIX officers and directors.
- Bought
- —
- Sold
- $12.8m
0 trades
28 trades
- Lyons Gary Asold
- Lyons Gary Asold
- Lyons Gary Asold
- Lyons Gary Asold
- Morrow George Jsold
- Morrow George Jsold
- Morrow George Jsold
- Morrow George Jsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 18, 2024 (29d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 18, 2024 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Nov 17, 2023 (21d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Nov 17, 2023 (21d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 20, 2023 (37d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 20, 2023 (37d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (51d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (51d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 20, 2023 (35d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 20, 2023 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (37d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (41d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (41d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
